ADARx Pharmaceuticals, Inc. (ADRX) Key Metrics
ADRX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.89B
- Enterprise value
- $1.82B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 307.7
- Price / book
- —
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
ADRX key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsADRX returns How much profit the business earns on the capital it uses.
Return on assets+0.1 pts
−19.7%
2025 · hover or tap a bar for each year
20242025
Asset turnover
0.01
2025 · hover or tap a bar for each year
20242025
ADRX per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.03
2025 · hover or tap a bar for each year
20242025
Earnings per share
−$0.72
2025 · hover or tap a bar for each year
20242025
Free cash flow per share
$2.54
2025 · hover or tap a bar for each year
20242025
Book value per share
−$1.98
2025 · hover or tap a bar for each year
20242025
Shares outstanding0.0%
102.2M
2025 · hover or tap a bar for each year
20242025
ADRX financial health Debt, liquidity and how easily interest is covered.
Net debt−$52.5M
−$66.5M
2025 · hover or tap a bar for each year
20242025
Current ratio−35.9%
16.18
2025 · hover or tap a bar for each year
20242025
ADRX returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ADRX debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ADRX key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.03 | $0.00 |
| Earnings per share | −$0.72 | −$0.45 |
| Operating cash flow per share | $2.57 | −$0.48 |
| Free cash flow per share | $2.54 | −$0.48 |
| Cash per share | $0.65 | $0.14 |
| Book value per share | −$1.98 | −$1.34 |
| Tangible book value per share | −$1.98 | −$1.34 |
| Capex per share | $0.03 | $0.00 |
| Shares outstanding | 102.2M | 102.2M |
| Change in shares outstanding | 0.0% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −19.7% | −19.9% |
| Return on tangible assets | −14.4% | −19.9% |
| Financial health | ||
| Cash & short-term investments | $66.5M | $14.0M |
| Net debt | −$66.5M | −$14.0M |
| Current ratio | 16.18 | 25.25 |
| Quick ratio | 16.18 | 25.25 |
| Working capital | $462.9M | $216.7M |
| Invested capital | −$268.8M | −$151.2M |
| Tangible asset value | −$202.3M | −$137.1M |
| Net current asset value | −$216.5M | −$144.9M |
| Graham net-net per share | −$6.30 | −$3.49 |
| Capital allocation | ||
| Capex / revenue | 85.1% | — |
| Capex / operating cash flow | 1.1% | — |
| Capex / depreciation | 1.26 | 0.30 |
| Stock-based compensation / revenue | 177.6% | — |
| R&D / revenue | 2,073.4% | — |
| SG&A / revenue | 588.6% | — |
| Efficiency | ||
| Asset turnover | 0.01 | 0.00 |
| Average payables | $3.6M | $1.3M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from ADRX's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ADRX valuation and financial ratios
See the ADRX income statement, the ADRX chart for price history, or the ADRX stock overview for the latest quote and news.
ADRX key metrics FAQ
What is ADARx Pharmaceuticals's current ratio?
ADARx Pharmaceuticals's current ratio was 16.18 at the end of fiscal 2025: current assets were 16.18 times current liabilities.